• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

    3.770 -0.030 (-0.79%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cellectar Biosciences, Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 13, 2025 ↗
     
    Via Benzinga
    News headline image
    Earnings Outlook For Cellectar Biosciences ↗
     
    Via Benzinga
    News headline image
    Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For August 14, 2025 ↗
     
    Via Benzinga
    News headline image
    A Peek at Cellectar Biosciences's Future Earnings ↗
     
    Via Benzinga
    News headline image
    Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
    CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall Survival 
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
    CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models 
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally ↗
    The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in... 
    Via Stocktwits
    Topics Supply Chain
    News headline image
    Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
    CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and Overall Survival 
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
    Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025 
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
    Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors 
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
    Presenting Data from CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Patients 
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Cuts Q2 Losses and Expenses ↗
    Via The Motley Fool
    News headline image
    Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Which stocks are moving on Tuesday? ↗
    Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Which stocks are experiencing notable movement on Tuesday? ↗
    Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
    Via Chartmill
    News headline image
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
    Via Chartmill
    News headline image
    Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
     
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.